{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-120789","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.825434+00:00","generated_at":"2026-05-16T13:13:02.645371+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Palvella Phase 2 TOIVA study: 73% of patients improved; plans FDA discussions for Breakthrough Therapy","bullets":["73% (11/15) improved on Overall cVM-IGA at Week 12; 67% rated \"Much Improved\" or \"Very Much Improved\".","Statistical significance on multiple endpoints, including Overall cVM-IGA (p<0.001) and PGI-C (p<0.001).","QTORIN rapamycin generally well-tolerated; no drug-related SAEs; most common AE application site erythema (25%).","Company plans near-term FDA discussions for Breakthrough Therapy Designation and Phase 3 pivotal study.","Potential first FDA-approved therapy for cutaneous venous malformations affecting >75,000 patients in US."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-120789","json":"https://secwatch.observer/filing/0001104659-25-120789.json","markdown":"https://secwatch.observer/filing/0001104659-25-120789.md","text":"https://secwatch.observer/filing/0001104659-25-120789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/0001104659-25-120789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/tm2533458d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:13:02.645371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}